A recent publication from the NIH using TILs genetically engineered with an inducible IL-12 for metastatic melanoma shows the utility of IL-12 in solid tumors allowing for the absence of IL-2 administration and lower cell doses than trials using conventional TILs [39]. Here, IL2 is linked to metastatic melanoma.